273 related articles for article (PubMed ID: 28647352)
1. How to Approach a Patient With Nonalcoholic Fatty Liver Disease.
Tilg H
Gastroenterology; 2017 Aug; 153(2):345-349. PubMed ID: 28647352
[No Abstract] [Full Text] [Related]
2. Nonalcoholic Fatty Liver Disease in Children: Unique Considerations and Challenges.
Goldner D; Lavine JE
Gastroenterology; 2020 May; 158(7):1967-1983.e1. PubMed ID: 32201176
[TBL] [Abstract][Full Text] [Related]
3. Nonalcoholic fatty liver disease and hepatic cirrhosis: Comparison with viral hepatitis-associated steatosis.
Haga Y; Kanda T; Sasaki R; Nakamura M; Nakamoto S; Yokosuka O
World J Gastroenterol; 2015 Dec; 21(46):12989-95. PubMed ID: 26675364
[TBL] [Abstract][Full Text] [Related]
4. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
Streba LA; Vere CC; Rogoveanu I; Streba CT
World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
[TBL] [Abstract][Full Text] [Related]
5. Screening for Nonalcoholic Fatty Liver Disease in Persons with Type 2 Diabetes in the United States Is Cost-effective: A Comprehensive Cost-Utility Analysis.
Noureddin M; Jones C; Alkhouri N; Gomez EV; Dieterich DT; Rinella ME;
Gastroenterology; 2020 Nov; 159(5):1985-1987.e4. PubMed ID: 32763241
[No Abstract] [Full Text] [Related]
6. Epidemiology and Natural History of Nonalcoholic Fatty Liver Disease.
Satapathy SK; Sanyal AJ
Semin Liver Dis; 2015 Aug; 35(3):221-35. PubMed ID: 26378640
[TBL] [Abstract][Full Text] [Related]
7. The story of HCC in NAFLD: from epidemiology, across pathogenesis, to prevention and treatment.
Margini C; Dufour JF
Liver Int; 2016 Mar; 36(3):317-24. PubMed ID: 26601627
[TBL] [Abstract][Full Text] [Related]
8. Foreword. Nonalcoholic Fatty Liver Disease.
Day CP; Anstee QM
Semin Liver Dis; 2015 Aug; 35(3):203-6. PubMed ID: 26378638
[No Abstract] [Full Text] [Related]
9. Guidelines of prevention and treatment of nonalcoholic fatty liver disease (2018, China).
Fan JG; Wei L; Zhuang H;
J Dig Dis; 2019 Apr; 20(4):163-173. PubMed ID: 30444584
[No Abstract] [Full Text] [Related]
10. Enriched MACK-3 following CHAI and MACK-3 for the noninvasive diagnosis of nonalcoholic steatohepatitis.
Polyzos SA; Kountouras J
Ann Hepatol; 2020; 19(5):579-580. PubMed ID: 32702498
[No Abstract] [Full Text] [Related]
11. [NASH (non-alcoholic steatohepatitis): fatty liver or fatal liver disease?].
Roeb E
Zentralbl Chir; 2014 Apr; 139(2):168-74. PubMed ID: 22441997
[TBL] [Abstract][Full Text] [Related]
12. Nonalcoholic Fatty Liver Disease: A Silent Epidemic.
Sivell C
Gastroenterol Nurs; 2019; 42(5):428-434. PubMed ID: 31574071
[TBL] [Abstract][Full Text] [Related]
13. Liver Biopsy in Chronic Liver Diseases: Is There a Favorable Benefit: Risk Balance?
Larrey D; Meunier L; Ursic-Bedoya J
Ann Hepatol; 2017; 16(4):487-489. PubMed ID: 28612749
[TBL] [Abstract][Full Text] [Related]
14. Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma: A Growing Epidemic?
Yopp AC; Choti MA
Dig Dis; 2015 Sep; 33(5):642-7. PubMed ID: 26398208
[TBL] [Abstract][Full Text] [Related]
15. Review of nonalcoholic fatty liver disease in women with polycystic ovary syndrome.
Kelley CE; Brown AJ; Diehl AM; Setji TL
World J Gastroenterol; 2014 Oct; 20(39):14172-84. PubMed ID: 25339805
[TBL] [Abstract][Full Text] [Related]
16. Alcoholic liver disease presents at advanced stage and progresses faster compared to non-alcoholic fatty liver diseas.
Shoreibah M; Raff E; Bloomer J; Kakati D; Rasheed K; Kuo YF; Singal AK
Ann Hepatol; 2016; 15(2):183-9. PubMed ID: 26845595
[TBL] [Abstract][Full Text] [Related]
17. Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance.
Stål P
World J Gastroenterol; 2015 Oct; 21(39):11077-87. PubMed ID: 26494963
[TBL] [Abstract][Full Text] [Related]
18. Preventing liver fibrosis in patients with NAFLD and the road ahead.
Nobili V; Miele L; Alisi A
Expert Rev Gastroenterol Hepatol; 2017 Dec; 11(12):1081-1083. PubMed ID: 28994314
[No Abstract] [Full Text] [Related]
19. Prevalence and Risk Factors of Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in General Population: the French Nationwide NASH-CO Study.
Nabi O; Lacombe K; Boursier J; Mathurin P; Zins M; Serfaty L
Gastroenterology; 2020 Aug; 159(2):791-793.e2. PubMed ID: 32376412
[No Abstract] [Full Text] [Related]
20. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update.
Athyros VG; Tziomalos K; Katsiki N; Doumas M; Karagiannis A; Mikhailidis DP
World J Gastroenterol; 2015 Jun; 21(22):6820-34. PubMed ID: 26078558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
